meta
|
evidence
oncology
Living systematic review and meta-analysis
NSCLC neoadjuvant setting
1
lung cancer : small cell (SCLC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab plus SoC
no study with result for this clinical condition